High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.

Slides:



Advertisements
Similar presentations
Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.
Advertisements

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.
Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
HIV Drug Resistance Control: the Latin American experience Giovanni Ravasi Pan-American Health Organization, Brazil International AIDS.
Global HIV Resistance: The Implications of Transmission
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
Prevalence of resistance mutations in a cohort of treatment-naïve people with chronic HIV infection in the U.S.: CPCRA 058 R M Novak 1, L Chen 2, R D MacArthur.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Linking HIV-1 and Antiretroviral Drug Resistance Surveillances: Low Prevalence of HIV-1 Drug Resistance in Peru Lama JR 1, Suarez L 2, Laguna A 3, Acuña.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.
Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages.
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA (Options in Management with Antiretrovirals) Trial Birgitt Dau, M.D. Postdoctoral.
Primary HIV-1 drug resistance in Canada: Updated results from the Canadian HIV Strain and Drug Resistance Surveillance Program Canadian HIV Strain and.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
ARV Therapy Basics in the Context of Family Planning
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Source: EPP/Spectrum HIV estimates, EPHI, 2014 HAART is the recommended form of treatment HAART is usually combination of at least 3 drugs 2 NRTIs +
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.
Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
Epidemiology Impaired Glucose Tolerance in HIV-Infected Drug Users By: Odell Aaron La Croix Mentor: Dr. Andrea Howard Work Site:Department of Epidemiology.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Assessment of Genetic Diversity and drug resistance mutations to current classes of inhibitors circulating in HIV -1 infected individuals in Nigeria Negedu-momoh,
Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.
2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
II IMB Meeting - Addis Ababa, October Integrated training activities and IT infrastructures to improve capacities in eastern African area JP
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
#AIDS2016 When Genes and ART Collide: Modifying Effect of ARVs on Genetic Predisposition to Diabetes Melissa A. Frasco, Ph.D. Research.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
DEPARTMENT OF PAEDIATRICS, THE QUEEN ELIZABETH HOSPITAL,
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Treatment of Latent TB Infection (LTBI)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
Background Results Methods Conclusion
Introduction Results Objectives Methods Conclusion Funding
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Dr. Velephi Okello, Principal Investigator, MaxART Trial
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Drug-resistant human immunodefiency virus
Impact of Baseline NNRTI Mutations on the Virologic Response to TMC125 in the Phase III Clinical Trials DUET-1 and DUET-2 J Vingerhoets, A Buelens, M.
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Silvia Bertagnolio, MD HIV Department World Health Organization
Comparison of NNRTI vs NNRTI
Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.
HVDRS STUDY RESISTANCE: WE CARE
Dr. Grace Namayanja – Kaye 24 July 2019
Share your thoughts on this presentation with #IAS2019
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez Giuliano 1, M. Martinez 2, C.G. Rodriguez 2, M.B. Bouzas 1. 1 Hospital Muñiz, Virology Unit, Buenos Aires, Argentina, 2 Hospital Cosme Argerich, Working Group in Prevention of Mother-to-Child Transmission, Buenos Aires, Argentina Background & Objective: The presence of primary mutations in the viral genome is a major cause of drug resistance. Monitoring the presence of drug resistance-associated mutations (RAMs) in HIV-infected pregnant women (HPW) is crucial for optimizing antiretroviral therapy (ART) selection. Until recently, genotypic resistance tests were not routinely available for HPW in Argentina and information about the prevalence of RAMs in this population is limited. We aimed to determine trends in the prevalence of RAMs in HPW assisted at a public hospital in Buenos Aires city (Hospital Argerich, located in La Boca commune, limiting Buenos Aires province). Methods: Prospective sentinel epidemiological survey. Baseline plasma samples were sequenced using TRUGENE TM HIV-1 Genotyping Kit at a reference laboratory (Hospital Muñiz, Virology Unit). RAMs were identified in ART-naïve (WHO guidelines) and ART-experienced patients (IAS-USA mutation list). RAMs prevalence was compared for two periods: vs AIDS 2016 #TUPDB0102

Results I 136 HPW were included: 77 (56.6%) naïve and 59 (43.4%) ART-experienced (24 with ongoing ART and 35 with a history of exposure to ART). A total of 37 (27.2%) women had at least one RAM: 25/94 (26.5%) in and 12/42 (28.5%) in (p>0.05). Naïve HPW: transmitted resistance was observed mainly for non-nucleoside reverse transcriptase inhibitors (NNRTIs): 14.3% in and 17.8% in (p>0.05), being K103N the most common mutation: 12.2% in and 10.7% in (p>0.05).

Results II Among the ART-experienced HPW, 37.3% had RAMs: 33.3% in and 50% in (p>0.05): In those with ongoing ART subgroup, 50% had nucleoside reverse transcriptase inhibitors-RAMs and 45.8% had NNRTI-RAMs. In those with a history of (but not ongoing) ART-exposure, 17.1% had NNRTI- RAMs. Predominant RAMs in experienced HPW were K103N (20,3%), M184V (11,8%) in RT gene and L90M (11,8%) in PR gene.  Conclusions:  This sentinel study demonstrates an overall high prevalence of RAMs in HPW in Buenos Aires city, which remained stable over the two periods analyzed.  Considering the >15% prevalence found in naïve HPW is above the threshold suggested by WHO for routine resistance surveillance in a certain population, access to genotypic tests should be warranted.  The moderate to high levels of NNRTI resistance observed, prevents empirical prescription of EFV or NVP-based ART in this population. Thank you !!!